Loading company…
SparingVision develops gene therapy treatments for inherited retinal diseases.
Founded in 2016 and based in Paris, SparingVision is a biotechnology company developing SPVN06, a gene therapy approach for inherited retinal diseases, including retinitis pigmentosa.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in